TRCT
HOWL icon

Tower Research Capital (TRC)’s Werewolf Therapeutics HOWL Stock Holding History

Tower Research Capital (TRC)’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,004
Closed -$11.8K – 5332
2025
Q3 		$11.8K Sell
6,004
-8,373
-58% -$11.5K ﹤0.01% 3841
2025
Q2 		$15.7K Buy
14,377
+5,235
+57% +$5.39K ﹤0.01% 3804
2025
Q1 		$8.89K Buy
9,142
+3,286
+56% +$4.3K ﹤0.01% 3844
2024
Q4 		$8.67K Buy
5,856
+600
+11% +$1.22K ﹤0.01% 3975
2024
Q3 		$11.1K Sell
5,256
-18,511
-78% -$42.1K ﹤0.01% 3691
2024
Q2 		$58K Buy
23,767
+13,230
+126% +$63.5K ﹤0.01% 2984
2024
Q1 		$68.3K Buy
+10,537
New +$61.4K ﹤0.01% 2071
2023
Q4 		– Sell
-2,350
Closed -$5.03K – 6029
2023
Q3 		$5.03K Sell
2,350
-477
-17% -$1.31K ﹤0.01% 4775
2023
Q2 		$8.62K Buy
2,827
+1,303
+85% +$3.67K ﹤0.01% 4402
2023
Q1 		$4K Sell
1,524
-5,622
-79% -$16.8K ﹤0.01% 5072
2022
Q4 		$15K Buy
7,146
+615
+9% +$1.61K ﹤0.01% 3417
2022
Q3 		$30K Buy
6,531
+4,188
+179% +$22.7K ﹤0.01% 3601
2022
Q2 		$10K Sell
2,343
-374
-14% -$1.71K ﹤0.01% 4451
2022
Q1 		$12K Buy
2,717
+2,065
+317% +$14.5K ﹤0.01% 4062
2021
Q4 		$8K Buy
652
+234
+56% +$3.53K ﹤0.01% 4787
2021
Q3 		$7K Buy
418
+366
+704% +$6.25K ﹤0.01% 4647
2021
Q2 		$1K Buy
+52
New +$712 ﹤0.01% 5209

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tower Research Capital (TRC)'s HOWL Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Werewolf Therapeutics (HOWL) in Q4 2025, closing a stake of 6,004 shares — an estimated $11.8K sold.

Tower Research Capital (TRC) first reported a position in HOWL in Q2 2021 and held it in 17 quarters. The position peaked at $68.3K in Q1 2024. 51 funds tracked by Wall St. Rank hold HOWL as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Werewolf Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 6,004 Werewolf Therapeutics shares in Q4 2025, an estimated $11.8K.
  • Tower Research Capital (TRC) first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 17 quarters.
  • Tower Research Capital (TRC)'s Werewolf Therapeutics position peaked at $68.3K in Q1 2024.
  • 51 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.